Medivation Stock Gaps Up On Today's Open (MDVN)

NEW YORK ( TheStreet) -- Shares of Medivation (Nasdaq: MDVN) were gapping up Wednesday morning with an open price 17.5% higher than Tuesday's closing price. The stock closed at $55.41 Tuesday and opened today's trading at $65.10.

The average volume for Medivation has been 926,800 shares per day over the past 30 days. Medivation has a market cap of $1.83 billion and is part of the health care sector and drugs industry. Shares are up 20.2% year to date as of the close of trading on Tuesday.

Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer's disease, and Huntington disease.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. You can view the full Medivation Ratings Report.

Get more investment ideas from our investment research center.

Interested in other stocks that are gapping up? Get free SMS text alerts sent to you when the action happens by texting UP to 95370 or select from multiple alert options.
null

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors